Navigation Links
Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
Date:3/29/2009

ical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (myocardial infarction or MI), or ischemia-driven target lesion revascularization (ID-TLR driven by lack of blood supply).

In addition, the SPIRIT II results demonstrated that XIENCE V continues to outperform TAXUS, with XIENCE V showing continued clinical benefits at three years, including an 88 percent reduction in the risk of cardiac death and a 57 percent reduction in the risk of MACE.

"In the clinical outcomes that matter most, such as heart attack, repeat procedure at the target lesion or death, XIENCE V demonstrated a consistent reduction compared to TAXUS out to three years," said Patrick W. Serruys, M.D., Ph.D., professor of Interventional Cardiology at Thoraxcentre, Erasmus University Hospital, Rotterdam, the Netherlands, and principal investigator of the SPIRIT II clinical trial. "What's even more impressive is that the clinical differences between XIENCE V and TAXUS continue to widen between two and three years, confirming the long-term safety and efficacy of XIENCE V."

In the 300-patient SPIRIT II trial, XIENCE V demonstrated the following key results at three years:

  • An 88 percent reduction in the risk of cardiac death compared to TAXUS (0.5 percent for XIENCE V vs. 4.2 percent for TAXUS, p-value=0.024)*.
  • A 57 percent reduction in the risk of MACE compared to TAXUS (6.4 percent for XIENCE V vs. 14.9 percent for TAXUS, p-value=0.029)*.
  • An observed 52 percent reduction in the risk of heart attacks (MI) compared to TAXUS (3.3 percent for XIENCE V vs. 6.8 percent for TAXUS, p-value=0.20)*.
  • An observed 56 percent reduction in the risk of ID-TLR compared to TAXUS (4.2 percent for XIENCE V vs. 9.4 percent for TAXUS, p-value=0.092)*.
  • No stent thrombosis between two and three years with XIENCE V,
    '/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
3. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
4. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
5. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
6. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
7. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
8. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
9. Medgenics Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
10. Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows
11. New Study Shows Probiotic Strain Effective in Improving Irritable Bowel Syndrome Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... LONDON , Sept. 30, 2014 ... market for molecular imaging informatics solutions including nuclear ... fusion and comparison. The study assesses the size ... between 2010 and 2013, and projects future growth ... well as the dynamics taking place in the ...
(Date:9/30/2014)... , Sept. 30, 2014  Decision Resources Group finds ... Brazil , Russia ... China (BRIC) will see robust expansion as ... favored over surgical procedures. Although revenues will be somewhat ... challenges, prolonged device approval times and demand for low-cost ...
(Date:9/30/2014)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) ... development and commercialization of prescription ophthalmic pharmaceuticals, announced today ... Hercules Technology Growth Capital, Inc. (NYSE: HTGC ... advance under the Loan and Security Agreement that Alimera,s ... Alimera Sciences Limited, entered into with Hercules in April ...
Breaking Medicine Technology:Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2
... CAMBRIDGE, Mass., Dec. 22, 2011  Inspiration Biopharmaceuticals, Inc. ... the development and commercialization of new treatment options ... Company has expanded its leadership team with four ... Inspiration as Chief Medical Officer; Daniel Regan as ...
... Dec. 22, 2011  PTC Therapeutics, Inc. (PTC) today ... Drug Discovery (SDD) Award from the Wellcome Trust ... target life-threatening infections caused by multidrug-resistant (MDR) Gram-negative ... Award from the Wellcome Trust to support its ...
Cached Medicine Technology:Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires 2Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires 3Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires 4Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires 5PTC Therapeutics' Antibacterial Program Receives $5 Million Award from the Wellcome Trust 2
(Date:9/30/2014)... Children conceived either less than one year or more than ... at increased risk for autism, a new study suggests. ... agree that the research can,t prove that birth spacing has ... important that parents understand that the odds for autism are ... far apart," said outside expert Dr. Andrew Adesman. He is ...
(Date:9/30/2014)... damaging "brain tsunamis" in injured patients without opening ... reality, thanks to pioneering research at the University ... team, led by Jed Hartings, PhD, research associate ... UC College of Medicine, has shown that spreading ... like tsunami wavescan be measured by the placement ...
(Date:9/30/2014)... lung cancer, breast cancer is the leading cause of ... Society. That,s why so many medical professionals encourage women ... at best: only a minority of suspicious mammograms actually ... lots of needless worry for women and their familiesnot ... tests, including ultrasounds and biopsies. , Recently, a ...
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling ... to treat Medicare patients has had no meaningful impact ... researchers in the Journal of Clinical Oncology ... outpatient chemotherapy to treat colorectal and lung cancers, and ... prescribe those drugs following the implementation of the recent ...
(Date:9/30/2014)... NJ (PRWEB) September 30, 2014 ... and wellness, is opening another new medical specialty practice ... IMA Cardiology will be located within the ... Ziad Abbud and Dr. Isaac Tawfik of American Heart ... N.J. The new practice will offer Integrated Medicine Alliance ...
Breaking Medicine News(10 mins):Health News:Spacing Between Sibling Births Tied to Autism Risk in Study 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:'Virtual breast' could improve cancer detection 2Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2
... say finding could be key to new disease-fighting therapies ... on mice suggests inhibiting a protein that allows certain ... to cancer-fighting treatments. , A study by Pierre Sonveaux ... found that tumor cells use different fuel sources depending ...
... A team of researchers at Duke University Medical Center and ... acid is an important energy source for tumor cells. In ... most hard-to-kill, dangerous tumor cells by preventing them from delivering ... than 50 years that low-oxygen, or hypoxic, cells cause resistance ...
... MORRISTOWN, N.J., Nov. 20 /PRNewswire/ Bayer HealthCare,has donated hundreds ... New Jersey,(CFBNJ) in response to an urgent call from ... supplies at the state,s food banks. , ... , Mary Lou Panzano, director, US Internal ...
... cancer patients who underwent a mastectomy who undergo ... reconstruction provides fewer long-term complications and better cosmetic ... to a study in the November issue of ... the official journal of the American Society for ...
... Alzheimer,s relatives at risk for hospital visits of their own ... providing care for a loved one with Alzheimer,s results in ... room or hospital visit every six months, says an Indiana ... care of an Alzheimer,s patient is difficult, but the Indiana ...
... Centre Finalizes Construction Plan and Begins Marketing; John Strong, ... Inc., to Lead Sales and Marketing Efforts , ... The world,s first permanent international healthcare marketplace and ... the key players driving the project said today, as ...
Cached Medicine News:Health News:Lactic acid found to fuel tumors 2Health News:Bayer HealthCare Donates Hundreds of Food Items to Community Food Bank of New Jersey in Response to Governor's Plea to Help the State's Population in Need 2Health News:Type of breast reconstruction impacts radiation therapy outcomes 2Health News:When the Caregiver Becomes the Patient 2Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 2Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 3Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 4Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 5
The 45 PSI SuperSportNeb provides superior performance that translates to shorter treatment times. Like the SportNeb, it is constructed with die-cast aluminum compressor components for consistent rel...
... PulmoAide Compact Compressor provides effective therapy at an ... therapy at home or on the go and ... the same reliable operation you have come to ... Compressor is the perfect solution for those patients ...
The 16 liter Laparoscopy Insufflator combines high safety and precise pressure control with simple operation....
Stryker's 40-liter insufflator provides superior performance with unprecedented safety and reliability....
Medicine Products: